AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
The excessive reactive oxygen species (ROS) accumulation and overactivated osteoclastogenesis in subchondral bone has proved to be a major cause of osteoarthritis (OA). Scavenging of ROS microenvironment to inhibit the osteoclastogenesis is highly valued in the therapeutic process of osteoarthritis. Despite the excellent ability of polyphenolic colloidal to scavenge reactive oxygen species and its affinity for macrophages, the preparation of polyphenolic colloidal nanoparticles is limited by the complex intermolecular forces between phenol molecules and the lack of understanding of polymerization/sol-gel chemistry. Herein, our work introduces a novel poly-tannin-phenylboronic colloidal nanoparticle (PTA) exclusively linked by ROS-responsive bondings. Nanocolloidal PTA has a uniform particle size, is easy and scalable to synthesize, has excellent scavenging of ROS, and can be slowly degraded. For in vitro experiments, we demonstrated that, PTA could eliminate ROS within RAW264.7 cells and impede osteoclastogenesis and bone resorption. RNA sequencing results of PTA-treated RAW264.7 cells further reveal the promotion of antioxidant activity and inhibition of osteoclastogenesis. For in vivo experiments, PTA could eliminate the ROS environment and reduce the number of osteoclasts in the subchondral bone, thereby alleviating the damage of subchondral bone and symptoms of osteoarthritis. Our research, by delving into the formation of polyphenol colloidal nanoparticles and validating their role in ROS scavenging to inhibit osteoclastogenesis in subchondral bone, may open new avenues for OA treatment in the future.
Wang, Y. Y.; Jones, G.; Keen, H. I.; Hill, C. L.; Wluka, A. E.; Kasza, J.; Teichtahl, A. J.; Antony, B.; O'Sullivan, R.; Cicuttini, F. M. Methotrexate to treat hand osteoarthritis with synovitis (METHODS): An Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial. Lancet 2023, 402, 1764–1772.
Nielsen, R. L.; Monfeuga, T.; Kitchen, R. R.; Egerod, L.; Leal, L. G.; Schreyer, A. T. H.; Gade, F. S.; Sun, C.; Helenius, M.; Simonsen, L. et al. Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning. Nat. Commun. 2024, 15, 2817.
Bittner, N.; Shi, C. F.; Zhao, D. Y.; Ding, J.; Southam, L.; Swift, D.; Kreitmaier, P.; Tutino, M.; Stergiou, O.; Cheung, J. T. S. et al. Primary osteoarthritis chondrocyte map of chromatin conformation reveals novel candidate effector genes. Ann. Rheum. Dis. 2024, 83, 1048–1059.
Hinman, R. S.; Campbell, P. K.; Kimp, A. J.; Russell, T.; Foster, N. E.; Kasza, J.; Harris, A.; Bennell, K. L. Telerehabilitation consultations with a physiotherapist for chronic knee pain versus in-person consultations in Australia: The PEAK non-inferiority randomised controlled trial. Lancet 2024, 403, 1267–1278.
Zhou, J.; Zhang, Z. Y.; Joseph, J.; Zhang, X. C.; Ferdows, B. E.; Patel, D. N.; Chen, W.; Banfi, G.; Molinaro, R.; Cosco, D. et al. Biomaterials and nanomedicine for bone regeneration: Progress and future prospects. Exploration 2021, 1, 20210011.
Davis, L. C.; Diianni, A. T.; Drumheller, S. R.; Elansary, N. N.; D'Ambrozio, G. N.; Herrawi, F.; Piper, B. J.; Cosgrove, L. Undisclosed financial conflicts of interest in DSM-5-TR: Cross sectional analysis. BMJ 2024, 384, e076902.
Duong, V.; Oo, W. M.; Ding, C. H.; Culvenor, A. G.; Hunter, D. J. Evaluation and treatment of knee pain: A review. JAMA 2023, 330, 1568–1580.
Fu, W. Y.; Vasylyev, D.; Bi, Y. F.; Zhang, M. S.; Sun, G. D.; Khleborodova, A.; Huang, G. W.; Zhao, L. B.; Zhou, R. P.; Li, Y. G. et al. Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis. Nature 2024, 625, 557–565.
Zou, Z. J.; Li, H.; Yu, K.; Ma, K.; Wang, Q. G.; Tang, J. N.; Liu, G. Z.; Lim, K.; Hooper, G.; Woodfield, T. et al. The potential role of synovial cells in the progression and treatment of osteoarthritis. Exploration 2023, 3, 20220132.
Yang, D. L.; Xu, J. W.; Xu, K.; Xu, P. Skeletal interoception in osteoarthritis. Bone Res. 2024, 12, 22.
Zheng, L. M.; Zhao, S.; Li, Y. X.; Xu, J. K.; Yan, W. J.; Guo, B. S.; Xu, J. B.; Jiang, L. F.; Zhang, Y. E.; Wei, H. et al. Engineered MgO nanoparticles for cartilage-bone synergistic therapy. Sci. Adv. 2024, 10, eadk6084.
Tian, H. S.; Gu, C. H.; Li, W. S.; Tong, T.; Wang, Y. S.; Yang, Y.; Wang, H. L.; Dai, Z. Q.; Chen, P. F.; Wang, F. et al. Neutralization of intracellular pH homeostasis to inhibit osteoclasts based on a spatiotemporally selective delivery system. Nano Lett. 2023, 23, 4101–4110.
Ro, D. H.; Cho, G. H.; Kim, J. Y.; Min, S. K.; Yang, H. R.; Park, H. J.; Wang, S. Y.; Kim, Y. J.; Lee, M. C.; Bae, H. C. et al. Selective targeting of dipeptidyl-peptidase 4 (DPP-4) positive senescent chondrocyte ameliorates osteoarthritis progression. Aging Cell 2024, e14161.
Wittoek, R.; Verbruggen, G.; Vanhaverbeke, T.; Colman, R.; Elewaut, D. RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial. Nat. Med. 2024, 30, 829–836.
Xin, X. R.; Liu, J. J.; Liu, X. C.; Xin, Y.; Hou, Y. B.; Xiang, X. C.; Deng, Y.; Yang, B.; Yu, W. X. Melatonin-derived carbon dots with free radical scavenging property for effective periodontitis treatment via the Nrf2/HO-1 pathway. ACS Nano 2024, 18, 8307–8324.
Zuo, G. L.; Zhuang, P. Z.; Yang, X. H.; Jia, Q.; Cai, Z. W.; Qi, J.; Deng, L. F.; Zhou, Z. H.; Cui, W. G.; Xiao, J. R. Regulating chondro-bone metabolism for treatment of osteoarthritis via high-permeability Micro/Nano hydrogel microspheres. Adv. Sci. 2024, 11, 2305023.
Zhou, T.; Xiong, H.; Yao, S. Y.; Wang, S. Q.; Li, S. F.; Chang, J. T.; Zhai, Z. H.; Guo, D. S.; Fan, C. Y.; Gao, C. Y. Hypoxia and Matrix metalloproteinase 13-responsive hydrogel microspheres alleviate osteoarthritis progression in vivo. Small 2024, 20, 2308599.
Durán-Sotuela, A.; Fernandez-Moreno, M.; Suárez-Ulloa, V.; Vázquez-García, J.; Relaño, S.; Hermida-Gómez, T.; Balboa-Barreiro, V.; Lourido-Salas, L.; Calamia, V.; Fernandez-Puente, P. et al. A meta-analysis and a functional study support the influence of mtDNA variant m.16519C on the risk of rapid progression of knee osteoarthritis. Ann. Rheum. Dis. 2023, 82, 974–984.
Jin, C.; Yu, X. B.; Yang, J. Y.; Lin, Z.; Ma, R. X.; Lin, B. H.; Zhang, H. J.; Dai, Z. H.; Xue, K. K.; Xie, C. L. et al. Corynoline suppresses osteoclastogenesis and attenuates ROS activities by regulating NF-κB/MAPKs and Nrf2 signaling pathways. J. Agric. Food Chem. 2024, 72, 8149–8166.
Wang, S. L.; Nikamo, P.; Laasonen, L.; Gudbjornsson, B.; Ejstrup, L.; Iversen, L.; Lindqvist, U.; Alm, J. J.; Eisfeldt, J.; Zheng, X. W. et al. Tapia-Paez, Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilans. EMBO Mol. Med. 2024, 16, 596–615.
Liu, S. T.; Zhang, C.; Zhou, Y. Y.; Zhang, F.; Duan, X. H.; Liu, Y.; Zhao, X. B.; Liu, J.; Shuai, X. T.; Wang, J. L. et al. MRI-visible mesoporous polydopamine nanoparticles with enhanced antioxidant capacity for osteoarthritis therapy. Biomaterials 2023, 295, 122030.
Côté, A. P.; Benin, A. I.; Ockwig, N. W.; O'keeffe, M.; Matzger, A. J.; Yaghi, O. M. Porous, crystalline, covalent organic frameworks. Science 2005, 310, 1166–1170.
Cheng, X. J.; Li, M. Y.; Wang, H.; Cheng, Y. Y. All-small-molecule dynamic covalent gels with antibacterial activity by boronate-tannic acid gelation. Chin. Chem. Lett. 2020, 31, 869–874.
Zheng, L. M.; Zhuang, Z. K.; Li, Y. X.; Shi, T. S.; Fu, K.; Yan, W. J.; Zhang, L.; Wang, P.; Li, L.; Jiang, Q. Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis. Bioact. Mater. 2022, 14, 250–261.
Lv, Z. Y.; Wang, P.; Li, W. T.; Xie, Y.; Sun, W.; Jin, X. Y.; Jiang, R. Y.; Fei, Y. X.; Liu, Y.; Shi, T. S. et al. Bifunctional TRPV1 targeted magnetothermal switch to attenuate osteoarthritis progression. Research 2024, 7, 0316.
Huang, T.; Zhang, T. Y.; Jiang, X. C.; Li, A.; Su, Y. Q.; Bian, Q.; Wu, H. H.; Lin, R. Y.; Li, N.; Cao, H. C. et al. Iron oxide nanoparticles augment the intercellular mitochondrial transfer-mediated therapy. Sci. Adv. 2021, 7, eabj0534.
